Twin Capital Management Inc. Sells 1,422 Shares of Elevance Health, Inc. $ELV

Twin Capital Management Inc. lessened its position in shares of Elevance Health, Inc. (NYSE:ELV) by 65.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 735 shares of the company’s stock after selling 1,422 shares during the quarter. Twin Capital Management Inc.’s holdings in Elevance Health were worth $215,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new position in shares of Elevance Health during the 4th quarter valued at approximately $31,000. J.Safra Asset Management Corp bought a new stake in Elevance Health in the fourth quarter worth $32,000. ORG Partners LLC raised its stake in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares in the last quarter. Dorato Capital Management purchased a new stake in Elevance Health during the fourth quarter valued at $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Elevance Health during the fourth quarter valued at $38,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 0.0%

ELV stock opened at $372.68 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $436.24. The stock has a market capitalization of $80.82 billion, a price-to-earnings ratio of 16.56, a price-to-earnings-growth ratio of 2.10 and a beta of 0.67. The firm’s fifty day simple moving average is $399.55 and its two-hundred day simple moving average is $355.35.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The firm had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. During the same quarter last year, the business earned $8.84 EPS. The business’s revenue was up .8% on a year-over-year basis. As a group, analysts anticipate that Elevance Health, Inc. will post 27.05 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s dividend payout ratio is 29.26%.

Wall Street Analysts Forecast Growth

ELV has been the topic of a number of research reports. Sanford C. Bernstein set a $488.00 target price on shares of Elevance Health in a report on Thursday. Raymond James Financial set a $450.00 price target on shares of Elevance Health in a report on Tuesday, July 7th. TD Cowen lifted their price target on Elevance Health from $400.00 to $465.00 and gave the stock a “buy” rating in a research report on Tuesday. Jefferies Financial Group reduced their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Finally, Morgan Stanley upped their price objective on Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $440.90.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance posted stronger-than-expected second-quarter results and raised its full-year outlook, which supports the bullish case for the stock. Elevance Health Beats Q2 And Raises Outlook While Leaving More Medicaid Markets
• Positive Sentiment: Several analysts turned more constructive after earnings, including Guggenheim raising its target to $455 and TD Cowen reiterating a Buy rating, suggesting confidence in upside from current levels. These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings
• Positive Sentiment: Barclays also maintained an Overweight rating, even though it trimmed its price target, which still implies meaningful upside and reflects continued analyst support. Barclays price target update on Elevance Health
• Neutral Sentiment: Elevance’s Q2 earnings call highlighted growth opportunities, but also acknowledged ongoing strain in parts of the business, making the near-term outlook more balanced than purely upbeat. Elevance Health earnings call: growth levers amid strain
• Negative Sentiment: Shares are being held back by margin pressure and concerns around the company’s Medicaid exposure, which some coverage framed as a reason the stock slipped despite the earnings beat. Elevance Health beats second-quarter forecasts but shares slide on margin pressure
• Negative Sentiment: Market commentary also noted ELV underperformed peers recently, indicating investor caution even after the earnings report. Elevance Health Inc. stock underperforms Thursday when compared to competitors

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.